Does April 18 order fast-track ibogaine after 88% PTSD drop claims?

Federal agencies are being pushed to move faster on psychedelic treatments for serious mental illness. An April 18 executive order tells HHS, FDA, and others to speed funding, trials, and approval pathways for drugs like ibogaine and psilocybin. Use is still limited to controlled clinical settings after standard therapies fail. The backdrop is a long-stalled effort to legitimize psychedelics in medicine, especially for veterans with PTSD, addiction, depression, and traumatic brain injury.

Administration allies are framing it as accelerated clinical access, not retail prescribing. The goal is to get supervised treatments into practice sooner if trials line up. Supporters point to a Stanford veteran cohort reporting large symptom drops one month after treatment: PTSD down 88%, depression 87%, anxiety 81%. That data is being used to argue urgency. The order leans on regulators to expand trials and define how these therapies are used. The immediate mechanism is bureaucratic pressure. Faster funding decisions, more trial support, and shorter approval timelines aimed at turning small studies into sanctioned treatment options.